Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;17(12):755-772.
doi: 10.1038/s41575-020-0314-8. Epub 2020 Jul 17.

Modern therapeutic approaches for the treatment of malignant liver tumours

Affiliations
Review

Modern therapeutic approaches for the treatment of malignant liver tumours

Henrik Petrowsky et al. Nat Rev Gastroenterol Hepatol. 2020 Dec.

Abstract

Malignant liver tumours include a wide range of primary and secondary tumours. Although surgery remains the mainstay of curative treatment, modern therapies integrate a variety of neoadjuvant and adjuvant strategies and have achieved dramatic improvements in survival. Extensive tumour loads, which have traditionally been considered unresectable, are now amenable to curative treatment through systemic conversion chemotherapies followed by a variety of interventions such as augmentation of the healthy liver through portal vein occlusion, staged surgeries or ablation modalities. Liver transplantation is established in selected patients with hepatocellular carcinoma but is now emerging as a promising option in many other types of tumour such as perihilar cholangiocarcinomas, neuroendocrine or colorectal liver metastases. In this Review, we summarize the available therapies for the treatment of malignant liver tumours, with an emphasis on surgical and ablative approaches and how they align with other therapies such as modern anticancer drugs or radiotherapy. In addition, we describe three complex case studies of patients with malignant liver tumours. Finally, we discuss the outlook for future treatment, including personalized approaches based on molecular tumour subtyping, response to targeted drugs, novel biomarkers and precision surgery adapted to the specific tumour.

PubMed Disclaimer

References

    1. Clavien, P. A., Petrowsky, H., DeOliveira, M. L. & Graf, R. Strategies for safer liver surgery and partial liver transplantation. N. Engl. J. Med. 356, 1545–1559 (2007). This review indicates the significance of safer strategies in liver surgery and partial liver transplantation and highlights tissue augmentation approaches by portal vein embolization and two-stage hepatectomy. - PubMed - DOI
    1. Cabibbo, G., Latteri, F., Antonucci, M. & Craxi, A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 6, 159–169 (2009). - PubMed - DOI
    1. Cassidy, S. & Syed, B. A. Colorectal cancer drugs market. Nat. Rev. Drug Discov. 16, 525–526 (2017). - PubMed - DOI
    1. Adam, R. et al. 2018 annual report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. Transpl. Int. 31, 1293–1317 (2018). - PubMed - DOI
    1. Bismuth, H. et al. Hepatic transplantation in Europe. First report of the European Liver Transplant Registry. Lancet 2, 674–676 (1987). - PubMed - DOI

Publication types